Furthermore, although there is pre-clinical evidence that ZEB1 induces PD-L1 expression in tumor cells by relieving miRNA-200 suppression (thus suggesting that the EMT phenotype may respond to checkpoint inhibitors) [25], the lack of PD-L1-positive DSRCT cells suggests that this is unlikely to have any therapeutic significance, although it goes without saying that the data must be confirmed in large case series. This evidence concerns the gene CD274 and neoplasm.